Kevin Conroy is the Chairman and CEO of Exact Sciences. Mr. Conroy led Exact Sciences through the development, clinical study, regulatory approval, and commercialization of its non-invasive colorectal cancer screening test, Cologuard®. In 2019, Exact Sciences’ acquisition of Genomic Health united two of the industry’s strongest brands, Cologuard and Oncotype DX®, and established the company’s position as a global leader in advanced cancer diagnostics. The company is working to improve screening, early detection, and treatment guidance throughout the cancer continuum.